[Hepatocardiac disorders : Interactions between two organ systems].

[1]  A. Shujaat,et al.  Effect of PAH Specific Therapy on Pulmonary Hemodynamics and Six-Minute Walk Distance in Portopulmonary Hypertension: A Systematic Review and Meta-Analysis , 2014, Pulmonary medicine.

[2]  M. Fallon,et al.  MELD Exceptions for Portopulmonary Hypertension: Current Policy and Future Implementation , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  Simona Bota,et al.  Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. , 2014, Gastroenterology.

[4]  C. Zauner,et al.  Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. , 2014, Journal of hepatology.

[5]  F. Bendtsen,et al.  Cirrhotic cardiomyopathy: pathogenesis and clinical relevance , 2014, Nature Reviews Gastroenterology &Hepatology.

[6]  T. Horvatits,et al.  Therapeutic options in pulmonary hepatic vascular diseases , 2014, Expert review of clinical pharmacology.

[7]  P. Schulze,et al.  Recent Advances in the Diagnosis and Management of Cirrhosis-Associated Cardiomyopathy in Liver Transplant Candidates: Advanced Echo Imaging, Cardiac Biomarkers, and Advanced Heart Failure Therapies , 2014, Clinical Medicine Insights. Cardiology.

[8]  R. Kumar,et al.  Correction: Updated clinical classification of pulmonary hypertension (Journal of the American College of Cardiology (2013) 62, (D34-D41)) , 2014 .

[9]  V. Fuhrmann,et al.  Schockleber und Cholestase beim kritisch Kranken , 2014, Medizinische Klinik - Intensivmedizin und Notfallmedizin.

[10]  S. Kluge,et al.  Pulmonale Komplikationen bei Lebererkrankungen , 2014, Medizinische Klinik - Intensivmedizin und Notfallmedizin.

[11]  Toru Satoh,et al.  Definitions and diagnosis of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[12]  M. Rodríguez-Gandía,et al.  Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine , 2013, Hepatology.

[13]  C. Zauner,et al.  Clinical impact of arterial ammonia levels in ICU patients with different liver diseases , 2013, Intensive Care Medicine.

[14]  C. Datz,et al.  Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II) , 2013, Wiener klinische Wochenschrift.

[15]  M. Trauner,et al.  Hypoxic liver injury and cholestasis in critically ill patients , 2013, Current opinion in critical care.

[16]  M. Fallon,et al.  Pulmonary vascular complications of liver disease. , 2013, American journal of respiratory and critical care medicine.

[17]  P. Angeli,et al.  Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms , 2013, Hepatology.

[18]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[19]  M. Sitges,et al.  LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. , 2013, Journal of hepatology.

[20]  C. Zauner,et al.  Jaundice increases the rate of complications and one‐year mortality in patients with hypoxic hepatitis , 2012, Hepatology.

[21]  N. Ortiz-Olvera,et al.  Anatomical cardiac alterations in liver cirrhosis: an autopsy study. , 2011, Annals of hepatology.

[22]  C. Madl,et al.  Impact of hypoxic hepatitis on mortality in the intensive care unit , 2011, Intensive Care Medicine.

[23]  Christian Melot,et al.  Deleterious effects of beta‐blockers on survival in patients with cirrhosis and refractory ascites , 2010, Hepatology.

[24]  C. Madl,et al.  Hypoxic hepatitis: underlying conditions and risk factors for mortality in critically ill patients , 2009, Intensive Care Medicine.

[25]  R. Wiesner,et al.  Survival in Portopulmonary Hypertension: Mayo Clinic Experience Categorized by Treatment Subgroups , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  M. Humbert,et al.  Portopulmonary hypertension: survival and prognostic factors. , 2008, American journal of respiratory and critical care medicine.

[27]  J. Henriksen,et al.  Cardiovascular complications of cirrhosis , 2008, Postgraduate Medical Journal.

[28]  C. Madl,et al.  Hepatopulmonary syndrome in patients with hypoxic hepatitis. , 2006, Gastroenterology.

[29]  R. Rodríguez-Roisín,et al.  Pulmonary–Hepatic vascular Disorders (PHD) , 2004, European Respiratory Journal.

[30]  J. Henriksen,et al.  Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. , 2004, Journal of hepatology.

[31]  J. Henriksen,et al.  Ablation of haemodynamically unstable right ventricular outflow tract ventricular tachycardia guided by non-contact mapping , 2002, Heart.

[32]  C. A. Ward,et al.  Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. , 2001, Gastroenterology.

[33]  A. Delannoy,et al.  Hypoxic hepatitis caused by acute exacerbation of chronic respiratory failure: A case‐controlled, hemodynamic study of 17 consecutive cases , 1999, Hepatology.